GCP
STOK icon

GSA Capital Partners’s Stoke Therapeutics STOK Stock Holding History

GSA Capital Partners’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,076
Closed -$225K – 2139
2025
Q4 		$225K Sell
7,076
-40,507
-85% -$1.22M 0.02% 1341
2025
Q3 		$1.12M Buy
47,583
+8,744
+23% +$150K 0.09% 335
2025
Q2 		$441K Buy
+38,839
New +$369K 0.03% 1010
2024
Q2 		– Sell
-97,508
Closed -$1.32M – 2009
2024
Q1 		$1.32M Sell
97,508
-4,599
-5% -$27.9K 0.1% 278
2023
Q4 		$537K Sell
102,107
-245,962
-71% -$1.05M 0.05% 749
2023
Q3 		$1.37M Buy
348,069
+291,443
+515% +$1.92M 0.12% 255
2023
Q2 		$602K Buy
56,626
+16,262
+40% +$173K 0.06% 627
2023
Q1 		$336K Sell
40,364
-31,208
-44% -$282K 0.03% 957
2022
Q4 		$661K Sell
71,572
-3,555
-5% -$37K 0.08% 431
2022
Q3 		$965K Buy
+75,127
New +$1.2M 0.13% 176
2022
Q2 		– Sell
-40,495
Closed -$852K – 1779
2022
Q1 		$852K Buy
40,495
+16,028
+66% +$321K 0.11% 240
2021
Q4 		$587K Buy
24,467
+14,714
+151% +$351K 0.07% 503
2021
Q3 		$248K Buy
+9,753
New +$272K 0.03% 1125

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GSA Capital Partners's STOK Position: Q1 2026 in Review

GSA Capital Partners sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 7,076 shares — an estimated $225K sold.

GSA Capital Partners first reported a position in STOK in Q3 2021 and held it in 13 quarters. The position peaked at $1.37M in Q3 2023. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • GSA Capital Partners reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 7,076 Stoke Therapeutics shares in Q1 2026, an estimated $225K.
  • GSA Capital Partners first reported a position in Stoke Therapeutics in Q3 2021 and held it in 13 quarters.
  • GSA Capital Partners's Stoke Therapeutics position peaked at $1.37M in Q3 2023.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.